B. Riley analyst Jeff Van Sinderen lowered the firm’s price target on Biote (BTMD) to $8 from $9 and keeps a Buy rating on the shares. The company’s Q1 revenue and adjusted EBITDA came in above expectations, the analyst tells investors in a research note. The firm trimmed the price target to reflect a reduced multiple.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTMD:
- Biote price target lowered to $4 from $6 at TD Cowen
- Biote Corp. Earnings Call: Mixed Results and Strategic Realignment
- Optimistic Growth Potential and Strategic Initiatives Justify Buy Rating Despite Challenges
- Biote price target lowered to $6 from $8 at Roth Capital
- Biote Corp. Reports Strong Q1 2025 Financial Results